Truist Securities Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $41

Benzinga Newsdesk www.benzinga.com Positive 82.7%

Neg 0% Neu 0% Pos 82.7%

Truist Securities analyst Gregory Renza maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and raises the price target from $36 to $41.